Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
BARCELONA, Spain--( BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more details about future product features across its global portfolio at the upcoming 19 th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, March 11-14, 2026.
“There is no better global stage than ATTD to showcase how we’re shaping the future of glucose biosensing around the world. This year's conference is especially meaningful for me as it marks my first major diabetes industry event as CEO," said Jake Leach, president and chief executive officer at Dexcom. "The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin. That growing body of evidence, combined with our continued innovation across the Dexcom portfolio, reflects our broader ambition to transform diabetes care and advance metabolic health worldwide.”
New evidence shows how Dexcom CGM can help improve long-term health and reduce hospitalizations across diabetes types 1,3-4
Dexcom is presenting several abstracts during the annual conference showcasing clinical and real-world evidence that support the benefits of glucose biosensing. Key abstract highlights include:
Dexcom’s upcoming product roadmap and commitment to innovation and education
ATTD in-person and virtual attendees will have the opportunity to learn more about Dexcom’s continued innovation and commitment to improving CGM education by attending the following symposia and presentations:
Dexcom’s presence at ATTD builds on the company’s recent retail launch of Dexcom G7 15 Day in the United States, further demonstrating the company’s leadership and continued commitment to driving forward product innovation, evidence generation and CGM education for the entire industry.
For more information about Dexcom presentations at ATTD and to register to virtually attend the conference, visit https://attd.kenes.com/.
About Dexcom
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.
Category: IR
1 Martens T, et al. One-Year Real-World Impact of Dexcom CGM on HbA1c in Non-Insulin-Treated Type 2 Diabetes: Evidence From U.S. Primary Care Registry Analysis. Presented at ATTD 2026. 2 Mader J, et al. A Reference Framework for Continuous Glucose Monitoring Training and Education Among Healthcare Professionals. Presented at ATTD 2026. 3 Nemlekar P, et al. RT-CGM Initiation is Associated with Reductions in DKA-Related Hospitalizations and ER Visits in Children and Adults with Type 1 Diabetes. Presented at ATTD 2026. 4 Beck S, et al. A Prospective, Multi-center Study of a CGM-Informed Basal Insulin Therapy Optimization System in People with Type 2 Diabetes. Presented at ATTD 2026.